Tao Xie, MD, PhD, specializes in the diagnosis and treatment of various movement disorders, including Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), cortical basal ganglionic degeneration (CBGD), Huntington's disease (HD) and chorea, tremor, dystonia, hemifacial spasm, blepharospasm, tics, and Tourette syndrome. He uses medications, botulinum toxin injection and deep brain stimulation surgery for treatment of these neurological conditions.
In his clinical research, Dr. Xie studies the effectiveness of deep brain stimulation for the treatment of various movement disorders. He is also actively involved in clinical trials and research in Parkinson’s disease, PSP, MSA and tremor, and also the role of the DatScan in movement disorders.
Dr. Xie is a physician in the University of Chicago Center for Parkinson's Disease and Movement Disorders. Dedicated as a Center for Advanced Research by the American Parkinson Disease Association, this multidisciplinary center combines clinical expertise with state-of-the-art therapies and groundbreaking research.
Columbia University Medical Center
NY
Fellowship - Movement Disorders
Emory University School of Medicine
GA
Residency - Neurology
Emory University School of Medicine
GA
Internship - Medicine
Johns Hopkins School of Medicine
MD
Research - Neurology
The University of Hong Kong
Ph.D. - Parkinson's Disease
Zhejiang University School of Medicine
China
MD
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome.
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
PMID: 36573662
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2022 Oct 17.
PMID: 36253611
Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy.
Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy. Mov Disord. 2022 10; 37(10):2110-2121.
PMID: 35997131
Recommendations for Virtual Administration of the PSP Rating Scale.
Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
PMID: 35810447
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
PMID: 35363932
Mucus Penetrating and Cell-Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery.
Fan W, Wei Q, Xiang J, Tang Y, Zhou Q, Geng Y, Liu Y, Sun R, Xu L, Wang G, Piao Y, Shao S, Zhou Z, Tang J, Xie T, Li Z, Shen Y. Mucus Penetrating and Cell-Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery. Adv Mater. 2022 Apr; 34(16):e2109189.
PMID: 35196415
Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report.
Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report. Front Hum Neurosci. 2021; 15:754091.
PMID: 35095448
Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy.
Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy. Front Neurol. 2021; 12:736784.
PMID: 34650511
Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer.
Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. J Pineal Res. 2021 Oct; 71(3):e12758.
PMID: 34289167
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators.
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators. Front Med (Lausanne). 2021; 8:662460.
PMID: 34458283